Investigational intravenous antibody-drug conjugate targeting a tumor-associated surface antigen; upon binding and internalization, it releases a cytotoxic payload to kill antigen-expressing tumor cells. Being evaluated in a first-in-human Phase 1 dose escalation/expansion study in advanced solid tumors.